Drawing for HALO

USPTO serial 98678393

HALO

Reviewed by CopyMark Law Group

Status 654
Filing date
Status date
Registration date
—
Examiner
WATSON, BRIDGET ANNE
Law office
TMO LAW OFFICE 128

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HALO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrea Christensen

Andrea Christensen Pfizer Inc.66 Hudson Boulevard EastNew York, NY 10001-2192United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of renal, liver and/or cardiometabolic conditions and/or diseasesACTIVE—
042Pharmaceutical product evaluation; Pharmaceutical research and development; Scientific and technological services, namely, research and design in the field of small molecules, peptides and biologicsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 8, 2026RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 20, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Feb 20, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 20, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 20, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 20, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 20, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 8, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 8, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Dec 8, 2025CNSLSUSPENSION LETTER WRITTEN—
Nov 4, 2025DOCKASSIGNED TO EXAMINER—
Aug 12, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 12, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 12, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
May 12, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 12, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 10, 2025DOCKASSIGNED TO EXAMINER—
Aug 1, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 1, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance